Form 4: Mineralys Therapeutics Officer Sells Shares Under 10b5-1 Trading Plan

David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics, sold shares of MLYS common stock on April 1, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• On April 1, 2025, David Malcom Rodman, the Chief Medical Officer of Mineralys Therapeutics, executed several transactions involving the company's common stock.
• Rodman exercised stock options to acquire 1,606 shares at a price of $1.08 per share.
• He then sold 30,574 shares at a weighted average price of $14.9978, with individual sales ranging from $14.50 to $15.48.
• Additionally, he sold 2,791 shares at a weighted average price of $16.0219, with prices ranging from $15.6434 to $16.2450.
• Finally, Rodman sold 22,406 shares at a price of $16.77 per share.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on October 25, 2024.
• Following these transactions, Rodman directly owns 116,704 shares of Mineralys Therapeutics common stock and holds options for 114,274 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-existing trading plan. There is no indication of positive or negative sentiment towards the company's prospects.

Industry Context

Form 4 filings are a routine part of the US stock market and are required by the SEC to ensure transparency when company insiders trade their company's stock. The use of a 10b5-1 trading plan is a common practice that allows insiders to sell shares over a period of time, while avoiding concerns about insider trading.

Stakeholder Impact

• The stock sales by a company officer could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates this concern.

Key Dates

Keywords

Mineralys Therapeutics, MLYS, David Malcom Rodman, Chief Medical Officer, Form 4, Stock Sale, 10b5-1 Trading Plan, Insider Trading